International Agency for Research on Cancer (IARC) - Summaries & Evaluations
VOL.: 26 (1981) (p. 341)
5. Summary of Data Reported and Evaluation
5.1 Experimental data
No data on the carcinogenicity or teratogenicity of treosulphan in
experimental animals were available to the Working Group.
The only available studies on chromosomal effects showed that it
produces chromosomal aberrations in plants.
5.2 Human data
Treosulphan has had limited use since 1969, almost exclusively in the
treatment of ovarian cancer.
The only epidemiological study indicates that use of this drug is
followed by an increased risk of acute nonlymphocytic leukaemia.
There is sufficient evidence for the carcinogenicity of treosulphan
For definition of the italicized terms, see Preamble Evaluation.
Subsequent evaluation: Suppl. 7 (1987)
Last updated: 8 April 1998